Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
SciSparc Ltd. ( (SPRC) ) has provided an announcement.
SciSparc Ltd. announced an amendment to its letter of intent (LOI) for spinning off its advanced clinical stage pharmaceutical portfolio and equity stake in SciSparc Nutraceuticals Inc. to Miza III Ventures Inc., a publicly traded company in Canada. This move aligns with SciSparc’s strategy to create shareholder value and will see SciSparc holding a controlling interest in the new entity, active in both pharmaceutical and supplement sectors. The agreement, if concluded, will enhance SciSparc’s industry positioning by potentially boosting its operational capabilities in these sectors.
More about SciSparc Ltd.
SciSparc Ltd. is a specialty clinical-stage pharmaceutical company that focuses on developing therapies to treat disorders and rare diseases of the central nervous system. Its portfolio is based on cannabinoid pharmaceuticals, including drugs targeting Tourette syndrome, Alzheimer’s disease, autism, pain, and status epilepticus. The company also controls a subsidiary selling hemp seed oil-based products on Amazon.
YTD Price Performance: -95.31%
Average Trading Volume: 830,426
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $2.37M
Learn more about SPRC stock on TipRanks’ Stock Analysis page.
